United Therapeutics Executive and Leadership Team

Harsh Hurkat, the Senior Analyst - Chief Financial Officer Org at United Therapeutics, manages complex financial modeling and capital allocation strategies. By evaluating investment opportunities in biotechnology, Hurkat supports the long-term fiscal health of the organization. This role involves deep collaboration with the Chief Financial Officer to ensure accurate reporting and resource optimization across all pharmaceutical development programs. Harsh Hurkat monitors market trends to provide actionable insights that drive corporate growth and operational efficiency. Through rigorous data analysis, the Senior Analyst - Chief Financial Officer Org identifies potential risks and opportunities within the global healthcare landscape. This analytical work directly informs the strategic direction of the company, ensuring that capital remains focused on high-impact medical research. By maintaining strict financial discipline, the Senior Analyst - Chief Financial Officer Org secures the necessary funding for ongoing clinical trials and manufacturing expansion, ultimately strengthening the market position of the firm.

Jeff Ross, the President, Miromatrix at United Therapeutics, leads the development and manufacturing of advanced organ technologies designed to address the critical shortage of transplantable organs. By managing the specialized operations of the Miromatrix division, Ross drives the engineering of bio-engineered tissues and organs. This role involves coordinating with research scientists and manufacturing teams to scale production capabilities for future clinical applications. Jeff Ross oversees the strategic integration of these novel technologies into the broader corporate portfolio, ensuring alignment with the mission of treating chronic diseases. Through the management of complex laboratory processes, the President, Miromatrix ensures that all manufacturing activities adhere to strict quality control and regulatory requirements. This leadership role focuses on expanding the reach of regenerative medicine to improve patient survival rates. By prioritizing innovation in organ manufacturing, the President, Miromatrix secures a competitive advantage in the biotechnology sector while advancing the overall medical impact of the organization.

Jeffrey Kase, the Vice President, Chief Information Officer at United Therapeutics, directs the digital infrastructure and cybersecurity frameworks essential for biotechnology operations. Overseeing the integration of advanced data systems, Kase ensures that research teams maintain secure access to critical pharmaceutical development information. This leadership role involves architecting scalable cloud solutions that support global clinical trials and manufacturing logistics. Jeffrey Kase manages the technological roadmap to enhance operational agility and data integrity across the enterprise. By implementing robust IT governance, the Vice President, Chief Information Officer protects proprietary research and patient data from emerging digital threats. This focus on technological excellence enables seamless collaboration between internal departments and external research partners. Through the deployment of cutting-edge software and hardware, the Vice President, Chief Information Officer drives digital transformation, ensuring that the company remains at the forefront of medical technology innovation while maintaining compliance with international data standards.

Gil Golden, the Chief Medical Officer at United Therapeutics, oversees the clinical development and regulatory strategy for innovative therapies targeting rare and life-threatening diseases. By guiding the medical research agenda, Golden ensures that all pharmaceutical candidates meet rigorous safety and efficacy standards before reaching patients. This role involves frequent interaction with regulatory bodies and the Board to align clinical milestones with corporate objectives. Gil Golden directs the design and execution of complex clinical trials, focusing on improving patient outcomes and quality of life. Through the application of deep medical expertise, the Chief Medical Officer identifies new therapeutic pathways that address significant unmet medical needs. This leadership position requires constant monitoring of global health trends to adapt research priorities accordingly. By fostering a culture of scientific excellence, the Chief Medical Officer accelerates the transition of breakthrough treatments from the laboratory to the commercial market, directly impacting the success of the company.

Alyssa Friedrich, the Executive Vice President & Chief People Officer at United Therapeutics, directs the human capital strategy and organizational development initiatives. By fostering a culture of innovation and inclusivity, Friedrich ensures that the company attracts and retains top-tier talent in the competitive biotechnology industry. This role involves designing comprehensive training programs and performance management systems that align employee contributions with corporate goals. Alyssa Friedrich oversees the implementation of workplace policies that support the well-being and professional growth of the entire workforce. Through strategic workforce planning, the Executive Vice President & Chief People Officer ensures that the organization possesses the necessary expertise to execute complex pharmaceutical research and manufacturing projects. This leadership position requires close collaboration with other C-suite executives to maintain organizational health and operational agility. By championing employee engagement, the Executive Vice President & Chief People Officer drives the internal culture that sustains the long-term success and mission-driven focus of the firm.